Family Medicine Flashcards
Breast Cancer Screening
Mammography to 50-74 yo q/2-3 years (Conditional recommendation, very low certainty evidence)
Lung Cancer Screening
LDCT q/ year, 55-74 yo with smoking history currently of >30 pack/year or quit <= 15 years ago, up to 3 consecutive times
Colorectal Cancer Screening
60-74 yo: FOBT or FIT q/2 years Or Flexible Sigmoidoscopy q/10 years (Strong recommendation, moderate quality evidence)
Cervical Cancer Screening
30-69 yo: Pap Smear or liquid bases cytology q/3 years.
> 70 yo with not proper screening: continued screening until 3 negatives.
Next step if Cervical cancer screening Normal
Routine screening in 3 years
Next step if Cervical Cancer Screening: Inadequate sample
Repeat cytology in 3 months
Next step if Cervical Cancer Screening: Adequate sample, no TZ
Routine screening in 3 years
Next step if Cervical Cancer Screening: ASCUS, <30 yo or not HPV testing available
Repeat cytology in 6 months.
And then If
Negative: repeat in 6 months
ASCUS: Colposcopy
Next step if cervical cancer screening ASCUS, >30yo
HPV-DNA testing.
If negative: repeat cytology in 1 year.
If positive: Colposcopy.
Next step if cervical screening ASC-H (Abnormal squamous cells cannot rule out HSIL)
Colposcopy
Next p if cervical cancer screening AGUS/atypical endocervical cells/ atypical endometrial cells
Colposcopy + endometrial sampling
Next step if cervical cancer screening LSIL
Colposcopy or repeat cytology in 6 months
Next step if cervical cancer screening HSIL
Colposcopy
Next step if cervical cancer screening squamous carcinoma / other malignant changes
Colposcopy
Prostate cancer screening
55-69yo, inconsistent evidence of small benefit of PSA test. There is no evidence that screening with PSA test reduces mortality at other ages.
Obesity Definition
Prevalent,
Complex,
Progressive,
Relapsing chronic disease that is characterized by abnormal/excessive body fat (adiposity)
BMI formula
Weight (kg) / height2 (m2)
Or
Weight (lbs) / height2 (inches2) x703
Normal BMI
18.5 - 24.9
Management
Canadian Adult Obesity Clinical Practice Guidelines (Obesity Canada, 2020)
- Step 1: recognize obesity as a chronic disease and obtain patient permission to treat
• Step 2:
-assess the patient using appropriate measures (i.e. height, weight, WC, and BMI calculation) - identify root causes
complications, and barriers to treatment
• Step 3: discuss treatment options - Step 4: agree on goals of therapy with the patient
- Step 5: follow-up and reassess
Obesity Treatment Options
Nutrition Physical activity Psychological and behavioral interventions Pharmacotherapy Bariatric surgery
Pharmacological treatment indication in obesity
BMI >27 kg/m2 and risk factors
or
BMI ≥30 kg/m2
Adjunct to lifestyle modifications:
consider if patient has not lost
0.5-1 kg (1-2 lb) per wk by
3-6 mo after lifestyle changes
Bariatric surgery indication in obesity
BMI ≥35 kg/m2 and risk factors or BMI >40 kg/m2 Consider if other weight loss attempts have failed. Requires lifelong medical monitoring
Dyslipidemia Screening
full lipid profile every 1-3 yr
in:
- males and females ≥40 yo or menopausal
- Any age adults with additional dyslipidemia risk factors
Risk Factors for screening for dyslipidemiA
-Men and women ages ≥40 (or postmenopausal) -First Nations or individuals of South Asian ancestry -Current cigarette smoking -T2DM -Arterial HTN -Family history of premature CVD (men <55, women <65 in 1st-degree relative) -Family history of dyslipidemia -Erectile dysfunction -Chronic kidney disease -Inflammatory disease (lupus, rheumatoid arthritis, psoriatic arthritis, IBD) -HIV infection -COPD -Clinical evidence of atherosclerosis or abdominal aortic aneurysm -Stigmata of dyslipidemia (arcus cornea, xanthelasma, or xanthoma) Obesity (BMI 230 kg/m?) -Hypertensive diseases of pregnancy
Dyslipidemia Assesment
-Dyslipidemia screening
-physical examination
-Glucose
-eGFR
-4, 1G, calculated HDL-C), glucose, and eGFR
(optional: apolipoprotein B, urine ACR)
-screen for secondary causes: hypothyroidism, chronic kidney disease, DM. nephrotic sundrome liver
disease
-Estimate risk category (FRS)
Dyslipidemia Treatment
Intensity and type of treatment is guided by “risk category” :
- Health behaviour interventions
- Pharmacologic therapy
Pharmacologic therapy Dyslipidemia
(If patient is not a high risk, employ consistent lifestyle modifications for at least 3 mo before considering drug therapy.)
- 1st line mono therapy: Statins
- If severe side effects: Ezetimibe
- Post acute coronary syndrome: Cholesterol absorption inhibitors + Simvastatin (reduces mortality)
Monitoring of pharmacologic treatment of dyslipidemia
- ALT, CK, creatinine at baseline and 6 wk later
- Fasting lipids every 6-12 mo